Breaking News

Quest To Acquire Celera Corp.

Quest Diagnostics, Inc. will acquire Celera Corp. for $671 million, providing Quest with access to genetic tests and an R&D pipeline focused on cardiovascular disease and cancer.

Quest Diagnostics, Inc. will acquire Celera Corp. for $671 million, providing Quest with access to genetic tests and an R&D pipeline focused on cardiovascular disease and cancer. The transaction is expected to close the end of April.

Celera focuses on sequencing the human genome and identifying links between genetic variations and disease states. Quest also recently announced plans to acquire the Athena Diagnostics business from Thermo Fisher Scientific Inc. for $740 million in cash. Athena is a provider of diagnostic tests for neurological conditions, including Alzheimer’s disease.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters